What Happened

Merck KGaA has agreed to acquire Silence Therapeutics, a UK biotech focused on siRNA therapeutics, for $1.3bn. The acquisition adds divesiran, a Phase III-ready therapy for phlebotomy-dependent polycythaemia vera (PV), to Merck's pipeline. Silence's broader programs include zerlasiran for cardiovascular risk and earlier-stage candidates for cholesterol, obesity, and immune diseases.

Who Is Affected

Integration teams at Merck KGaA and Silence Therapeutics will lead the transition through Q1 2027. Vendors supporting clinical trial management, regulatory submissions, and post-merger integration should engage with these teams. The deal also impacts CROs and technology providers serving the siRNA and rare disease space.

Market Impact

This acquisition strengthens Merck's position in precision medicines and haematology after its 2025 acquisition of SpringWorks Therapeutics. Key implications:

• Expands Merck's RNA-based pipeline into rare blood cancers, a high-need area with limited treatment options.
• Silence's siRNA platform adds a complementary modality to Merck's existing drug development capabilities.
• The Phase II SANRECO data (88% responder rate, 0.2 mean phlebotomies vs 2.1 placebo) supports rapid Phase III initiation.

What to Watch

Watch for integration announcements around the divesiran Phase III program and potential pipeline prioritization. The deal's close in Q1 2027 provides a clear timeline for vendors to position solutions for clinical trial expansion and regulatory strategy. Also monitor how Merck balances Silence's programs with its broader portfolio post-SpringWorks.

Related coverage

• Merck KGaA acquires Silence Therapeutics in $1.3B siRNA blood cancer deal
• Mankind Pharma acquires 70% stake in Belgium CAR-T biotech ACTx for €48M
• STERIS agrees to acquire surgical safety firm Xodus Medical for $2.1B
• Ofichem acquires US CDMO Kinentia Biosciences to expand transatlantic network